Physician profile
Alexia Munter
NPI 1407384902
$4,018.02
in general payments reported to CMS, 2019-2025
19 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,107 · 2024: $1,712 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.03 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $855.76 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $714.36 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $524.22 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $306.27 | 2023-2025 | |
| Genentech USA, INC. | $278.42 | 2024-2025 | Xolair |
| Csl Behring | $229.27 | 2023-2025 | Hizentra, Haegarda |
| Kaleo, INC. | $174.63 | 2023-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $161.68 | 2023-2025 | |
| Grifols USA, LLC | $160.52 | 2023-2025 | Xembify |
| Optinose US, INC. | $144.36 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $98.36 | 2025 | Neffy |
| Abbvie INC. | $96.29 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.56 | 2024-2025 | Eohilia, Hyqvia, Takhzyro |
| Hikma Pharmaceuticals USA | $65.62 | 2023-2025 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $21.98 | 2025 | Nemluvio |
| Organon LLC | $21.39 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.64 | 2025 | Alvesco |
| Lilly USA, LLC | $15.70 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexia Munter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.